{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T21:39:53Z","timestamp":1767994793800,"version":"3.49.0"},"reference-count":37,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2008,3,17]],"date-time":"2008-03-17T00:00:00Z","timestamp":1205712000000},"content-version":"vor","delay-in-days":10699,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[1978,12]]},"abstract":"<jats:title>SUMMARY<\/jats:title><jats:p>The present study was undertaken to evaluate long\u2010term effects of spironolactone on basal serum oestrone, oestradiol, testosterone, LH and prolactin concentrations in hypertensive male patients. Serum prolactin response to TRH was also evaluated. Patients were divided into two groups: a conventional\u2010dosage group, consisting of six males with essential hypertension who took 75 to 150 mg of spironolactone daily for 12 weeks, and a high\u2010dosage group, consisting of two males with idiopathic hyperaldosteronism who took 300 mg of spironolactone daily for more than 40 weeks.<\/jats:p><jats:p>In the conventional\u2010dosage group, serum oestrone concentrations significantly increased (<jats:italic>P<\/jats:italic> &gt; 0.01) at 12 weeks, serum oestradiol concentrations gradually increased throughout the study period, however, the increments were not statistically significant (<jats:italic>P<\/jats:italic> &gt; 0.2). Basal serum testosterone, LH and prolactin concentrations were not significantly changed throughout the study period. Enhancement of serum prolactin response to TRH was not found in any of the patients in the conventional\u2010dosage group.<\/jats:p><jats:p>In the high\u2010dosage group, serum oestrone maintained high levels from the beginning of this study, and serum oestradiol concentrations increased with the development of gynaecomastia. Serum testosterone, LH and prolactin concentrations did not show any definite change throughout the study period.<\/jats:p><jats:p>Thus, long\u2010term spironolactone treatment increased the serum levels of oestrone and oestradiol in hypertensive men followed by the development of gynaecomastia. The elevations in circulating oestrogens could well explain the oestrogenic side\u2010effects of spironolactone treatment.<\/jats:p>","DOI":"10.1111\/j.1365-2265.1978.tb01510.x","type":"journal-article","created":{"date-parts":[[2008,3,17]],"date-time":"2008-03-17T13:28:35Z","timestamp":1205760515000},"page":"523-533","source":"Crossref","is-referenced-by-count":20,"title":["INCREASED SERUM OESTRONE AND OESTRADIOL FOLLOWING SPIRONOLACTONE ADMINISTRATION IN HYPERTENSIVE MEN"],"prefix":"10.1111","volume":"9","author":[{"given":"AKIHIKO","family":"MIYATAKE","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KEIZO","family":"NOMA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KIYOHIDE","family":"NAKAO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YASUHIKO","family":"MORIMOTO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YUICHI","family":"YAMAMURA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,3,17]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-29-6-866"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-44-6-1190"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-42-4-696"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/0303-7207(74)90012-4"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.3.5929.520-b"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-45-2-255"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-37-3-488"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1965.03090020077026"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1210\/endo-97-1-52"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/00032717208066108"},{"key":"e_1_2_1_12_1","first-page":"104","article-title":"The effect of Soldactona (canrenoate\u2010potassium) on plasma testosterone and androstenedione and urinary 17\u2010ketosteroids and 17\u2010hydroxy\u2010corticosteroids","volume":"70","author":"Dymling J.F.","year":"1972","journal-title":"Acta Endocrinologica"},{"key":"e_1_2_1_13_1","first-page":"53","article-title":"Reduced plasma testosterone following spironolactone in man","author":"Dymling J.F.","year":"1973","journal-title":"Acta Endocrinologica"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-128X(75)80009-2"},{"key":"e_1_2_1_15_1","first-page":"527","article-title":"Studies on prolactin in man","volume":"28","author":"Frantz A.G.","year":"1972","journal-title":"Recent Progress in Hormone Research"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI106859"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-128X(70)80124-6"},{"key":"e_1_2_1_18_1","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jama.1973.03220280028007","article-title":"Adverse reactions to spironolactone, A report from the Boston Collaborative Drug Surveillance Program","volume":"225","author":"Greenblatt D.J.","year":"1973","journal-title":"Journal of the American Medical Association"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-36-6-1069"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1976192158"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.211.12.2014"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-85-5-630"},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.1507\/endocrine1927.49.3_629"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1210\/endo-94-6-1628"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.1978.tb00806.x"},{"key":"e_1_2_1_26_1","first-page":"439","article-title":"The effect of spironolactone on plasma levels and excretion of testosterone and oestrogens in the urine in males","volume":"2","author":"Pentikaeinen P.J.","year":"1974","journal-title":"Journal of Internal Medical Research"},{"key":"e_1_2_1_27_1","doi-asserted-by":"publisher","DOI":"10.1210\/endo-97-6-1521"},{"key":"e_1_2_1_28_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-87-4-398"},{"key":"e_1_2_1_29_1","first-page":"686","article-title":"Pharmacokinetics of spironolactone, canrenone and canrenoate\u2010K in humans","volume":"185","author":"SAD\u00c9E W.","year":"1973","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"e_1_2_1_30_1","first-page":"301","article-title":"Aldosterone plasma radioimmunoassay interference by a spironolactone metabolism","volume":"25","author":"SAD\u00c9E W.","year":"1975","journal-title":"Steroids"},{"key":"e_1_2_1_31_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-43-6-1386"},{"key":"e_1_2_1_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(66)91005-1"},{"key":"e_1_2_1_33_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-41-4-777"},{"key":"e_1_2_1_34_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-41-4-791"},{"key":"e_1_2_1_35_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-44-6-1200"},{"key":"e_1_2_1_36_1","first-page":"279","article-title":"Effect of spironolactone on adrenal and gonadal steroids in man","volume":"24","author":"Taylor A.A.","year":"1976","journal-title":"Clinical Research"},{"key":"e_1_2_1_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(62)90814-0"},{"key":"e_1_2_1_38_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0028-1095668"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2265.1978.tb01510.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2265.1978.tb01510.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T17:49:02Z","timestamp":1699724942000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2265.1978.tb01510.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1978,12]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1978,12]]}},"alternative-id":["10.1111\/j.1365-2265.1978.tb01510.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2265.1978.tb01510.x","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[1978,12]]}}}